Amendment: SEC Form 10-Q/A filed by Centessa Pharmaceuticals plc
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
* | Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market, LLC. |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
Emerging growth company |
Item 6. Exhibits
Exhibit number |
Description of exhibit | |
31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (1) | |
31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (1) | |
101 INS | XBRL Instance Document | |
101 SCH | XBRL Taxonomy Extension Schema Document | |
104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibit 101.) |
(1) | Filed herewith |
4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CENTESSA PHARMACEUTICALS PLC | ||||||
Date: February 14, 2025 | By: | /s/ Saurabh Saha, M.D., Ph.D. | ||||
Name: Saurabh Saha, M.D., Ph.D. | ||||||
Title: Chief Executive Officer (Principal Executive Officer) |
Date: February 14, 2025 | By: | /s/ John Crowley | ||||
Name: John Crowley | ||||||
Title: Chief Financial Officer (Principal Financial Officer) |
5